Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of ASP0598 Otic Solution in Chronic Tympanic Membrane Perforation
NCT04305184Phase 2Terminated
- Sponsor
- Astellas Pharma
- Start
- Sep 2020
- Primary completion
- Jan 2023
- Modality
- Hormones & Growth Factors
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ASP0598 in chronic tympanic membrane perforation (8 arms), sponsored by Astellas Pharma. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events at Day 85, Number of Participants With AE of Special Interest as Cholesteatoma or Ear Neoplasm at Day 85 and 4 more. Started Sep 2020; status: terminated.
02
Drugs
ASP0598
03
Conditions
chronic tympanic membrane perforation
Beyond the preview
Go deeper on NCT04305184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04305184.